GenSpera, Inc.

Industry · 7 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Glioblastoma	Phase 2	2016-09-01
Completed	Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Clear Cell Renal Cell Carcinoma	Phase 2	2016-06-01
Completed	G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer Prostatic Neoplasms	Phase 2	2016-02-01
Completed	Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastom Glioblastoma Multiforme	Phase 2	2014-02-01
Withdrawn	Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer Prostate Cancer.	Phase 2	2013-05-01
Completed	Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Advanced Adult Hepatocellular Carcinoma	Phase 2	2013-01-01
Completed	Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors Advanced Solid Tumors	Phase 1	2010-01-01